SEC Form 4 · accession 0001485003-16-000170
Sesen Bio, Inc. · SESN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John J McCabe
Officer — Chief Financial Officer
Period of report
Sep 20, 2016
Accepted (ET)
Sep 22, 2016 · 4:48 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001485003
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $0.28 | Sep 20, 2016 | A | 6,664 | A | Sep 20, 2016 | Feb 24, 2026 | Common Stock | 6,664 | 20,000 | D |
| Stock Option (Right to Buy)F2 | $3.37 | Sep 20, 2016 | A | 100,000 | A | — | Sep 19, 2026 | Common Stock | 100,000 | 100,000 | D |
Explanation of responses
- F1On February 25, 2016, the reporting person was granted an option to purchase 20,000 shares of common stock. This option vests in installments based on the achievement of certain regulatory and business milestones. The Compensation Committee of the Company determined that one of these performance milestones was met, resulting in vesting of the option with respect to 6,664 shares. The option had previously vested with respect to 13,336 shares.
- F225% of the shares subject to such option shall vest on the first anniversary of the date of grant of the option and an additional 6.25% of the shares underlying the option shall vest at the end of each successive three-month period thereafter until the fourth anniversary of the date of grant of the option.